New device aims to stop deadly postpartum bleeding when drugs fail

NCT ID NCT06646653

Recruiting now Disease control Sponsor: ResQ Medical Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called the Alma system for women who have severe bleeding after childbirth that does not stop with standard treatments. About 50 women who experience heavy bleeding after vaginal or C-section delivery will be enrolled. If usual care fails, the Alma system is used to try to control the bleeding. Participants are followed until 6 weeks after birth to check safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM HAEMORRHAGE (PPH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Familial Primary Pulmonary Hypertension Postpartum Hemorrhage pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM HAEMORRHAGE (PPH) POSTPARTUM HEMORRHAGE (PRIMARY) PPH

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Maimonides Medical Center | Brooklyn, New York Hospital
NOT_YET_RECRUITING

Brooklyn, New York, 11219, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shaare Zedek Medical Center
RECRUITING

Jerusalem, 9103102, Israel

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.